QGEN
USDQiagen N.V. Common Shares
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$45.320
Kõrge
$47.355
Madal
$43.260
Maht
0.66M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
9.6B
Tööstusharu
Diagnostics & Research
Riik
Netherlands
Kauplemisstatistika
Keskmine maht
1.21M
Börs
NYQ
Valuuta
USD
52 nädala vahemik
Seotud uudised
QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025
QIAsymphony Connect, the next generation of automated nucleic acid purification platform, to be shown at AMP 2025 as early access phase begins ahead of full release in mid-2026 QIAGEN showcases Sample to Insight
QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions
Parse Biosciences is a fast-growing innovator in single-cell sample preparation, with technologies used in more than 3,000 labs across over 40 countries Acquisition strengthens QIAGEN's presence in the rapidly
QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase
Q3 2025 results: Net sales of $533 million (+6% at actual rates); diluted EPS $0.60 Core sales +6% CER (constant exchange rates) driven by QIAstat-Dx (+11% CER), QuantiFERON (+11% CER) and Sample technologies (+3%
QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025
New EZ2 DNA Investigator Sep&Prep Kit automates sexual assault sample processing, improving sperm DNA recovery and separation from victim DNA Workflow on EZ2 Connect Fx delivers high-quality DNA in under 2.5
QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing
QIAcube Connect drives lab efficiency by automating critical steps in molecular biology workflows for both research and clinical customers Milestone builds on nearly 13,000 cumulative placements of QIAcube family
Seotud aktsiad
SONN
Sonnet BioTherapeutics Holdings Inc.
CLB
Core Laboratories Inc.
CEROW
CERo Therapeutics Holdings Inc. Warrants
NAMS
NewAmsterdam Pharma Company N.V. Ordinary Shares
HYPR
Hyperfine Inc.
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.